




RealRate

PHARMACEUTICAL 2015

Alnylam Pharmaceuticals INC
Rank 71 of 274

Alnylam@20



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Alnylam Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 354%, being 100% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	746,367
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	95,334
Liabilities, Non-Current	0
Other Assets	311,488
Other Compr. Net Income	29,046
Other Expenses	-40,209
Other Liabilities	47,994
Other Net Income	54,937
Other Revenues	0
Property and Equipment	21,740
Research and Development	411,015
Selling, General and Administrative Expense	44,526

Output Variable	Value in 1000 USD
Assets	1,079,595
Liabilities	143,328
Expenses	415,332
Revenues	0
Stockholders Equity	936,267
Net Income	-360,395
Comprehensive Net Income	-345,872
BaseVar	861,119
ECR before LimitedLiability	277%
Economic Capital Ratio	354%